Literature DB >> 9520305

A rapid evaluation of phagocytosis and killing of Candida albicans by CD13+ leukocytes.

M Saresella1, K Roda, L Speciale, D Taramelli, E Mendozzi, F Guerini, P Ferrante.   

Abstract

Flow cytometry can be adopted for routine monitoring of the immune functions of human polymorphonuclear leukocytes (PMNs) in several disease states. We recently developed a rapid and reproducible assay for the evaluation of the phagocytosis and killing of Candida albicans blastospores by human PMNs. Whole blood leukocytes were incubated with opsonized fluorescein isothiocyanate-labeled (FITC-labeled) blastospores for phagocytosis and killing assays. To discriminate between ingested, membrane-bound and free C. albicans blastospores, ethidium bromide (EtBr) was added to the samples prior to the flow cytometric analysis. EtBr induces a loss of green fluorescence in non-phagocytized C. albicans blastospores. Phagocytosis is determined by gating the phagocytes and calculating the percentage of phagocyte-associated green fluorescent cells. Intracellular killing is determined by first lysing phagocytes by hypotonic shock and then adding propidium iodide (PI) in order to identify red dead blastospores. Killing is measured in terms of the percentage of double-marked blastospore cells. We suggest that this method is a reliable and inexpensive technique to evaluate the immune reactivity of PMNs and peripheral blood monocytes (PBMs) in cases of immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9520305     DOI: 10.1016/s0022-1759(97)00196-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  7 in total

1.  Mast cells kill Candida albicans in the extracellular environment but spare ingested fungi from death.

Authors:  Elisa Trevisan; Francesca Vita; Nevenka Medic; Maria Rosa Soranzo; Giuliano Zabucchi; Violetta Borelli
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

2.  Macrophage-mediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene.

Authors:  Mathieu Goupil; Emilie Bélanger Trudelle; Véronique Dugas; Catherine Racicot-Bergeron; Francine Aumont; Serge Sénéchal; Zaher Hanna; Paul Jolicoeur; Louis de Repentigny
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

3.  A homozygous CARD9 mutation in a Brazilian patient with deep dermatophytosis.

Authors:  Anete S Grumach; Flavio de Queiroz-Telles; Mélanie Migaud; Fanny Lanternier; Nelson Rosario Filho; Sandra M U Palma; Rosemeire Navickas Constantino-Silva; Jean Laurent Casanova; Anne Puel
Journal:  J Clin Immunol       Date:  2015-06-05       Impact factor: 8.317

4.  Steroid receptor coactivator 3 is required for clearing bacteria and repressing inflammatory response in Escherichia coli-induced septic peritonitis.

Authors:  Qiang Chen; Tenghui Chen; Yixiang Xu; Jingwei Zhu; Yuan Jiang; Yang Zhao; Jianming Xu; Chundong Yu
Journal:  J Immunol       Date:  2010-09-29       Impact factor: 5.422

5.  Gene expression in HL60 granulocytoids and human polymorphonuclear leukocytes exposed to Candida albicans.

Authors:  Alaka Mullick; Miria Elias; Penelope Harakidas; Anne Marcil; Malcolm Whiteway; Bing Ge; Thomas J Hudson; Antoine W Caron; Lucie Bourget; Serge Picard; Orce Jovcevski; Bernard Massie; David Y Thomas
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1.

Authors:  Miriam Marquis; Daniel Lewandowski; Véronique Dugas; Francine Aumont; Serge Sénéchal; Paul Jolicoeur; Zaher Hanna; Louis de Repentigny
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

Review 7.  Inherited CARD9 Deficiency: Invasive Disease Caused by Ascomycete Fungi in Previously Healthy Children and Adults.

Authors:  Emilie Corvilain; Jean-Laurent Casanova; Anne Puel
Journal:  J Clin Immunol       Date:  2018-08-22       Impact factor: 8.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.